Investors in Series A

IAG Silverstripe is the investment arm of IAG Capital, focusing on strategic investments across various sectors. The firm provides capital and strategic support to businesses with growth potential, aiming to maximize returns and strategic synergies within IAG Capital's portfolio. With a focus on identifying promising opportunities and fostering long-term partnerships, IAG Silverstripe plays a pivotal role in enhancing the value and diversification of IAG Capital's investment portfolio. For more detailed information about their investment strategies and portfolio, visiting their official website or contacting IAG Silverstripe directly would provide comprehensive insights into their operations and impact.

IAG Silverstripe is the investment arm of IAG Capital, focusing on strategic investments across various sectors. The firm provides capital and strategic support to businesses with growth potential, aiming to maximize returns and strategic synergies within IAG Capital's portfolio. With a focus on identifying promising opportunities and fostering long-term partnerships, IAG Silverstripe plays a pivotal role in enhancing the value and diversification of IAG Capital's investment portfolio. For more detailed information about their investment strategies and portfolio, visiting their official website or contacting IAG Silverstripe directly would provide comprehensive insights into their operations and impact.

The BaseLaunch accelerator is tailored to the needs of healthcare startups. BaseLaunch is the Basel-based incubator and accelerator that helps scientists and entrepreneurs launch exceptional biotech companies. It serves as a growth platform for early-stage ventures developing cutting-edge therapeutics. Accelerating Therapeutic Ventures.

The $50 million fund managed by EA Ventures is designed to operate over a span of five years, targeting early-stage startups primarily at the Seed and Pre-Series A stages. EA Ventures typically invests between $0.5 million to $2 million per company, focusing on startups that have demonstrated traction and are poised for growth. This fund aims to support innovative ventures across various sectors, providing capital to fuel their development and expansion efforts during critical phases of their business lifecycle. Their strategic investment approach aims to nurture promising startups and help them achieve significant milestones on their path to scaling and market success.

Siena Secondary Fund provides liquidity for early investors, founders and employees of high growth startups from the Nordics & CEE region. We target companies which are usually post series A, have solid business model and are still in high growth phase.

Prefcap is dedicated to backing B2B software companies in Europe with bite-sized funding between Seed and Series B stages. Specializing in supporting early to mid-stage startups, Prefcap provides strategic capital to fuel growth and expansion. Their investment focus is on innovative B2B software solutions that have the potential to disrupt industries and scale globally. By offering flexible financing options and strategic guidance, Prefcap empowers entrepreneurs to navigate the challenges of scaling their businesses successfully. Committed to fostering innovation and entrepreneurship in Europe, Prefcap serves as a valuable partner for ambitious founders aiming to achieve market leadership in the technology sector.

Acceleris Capital, under KPMG Acceleris, specializes in arranging new capital for SMEs and makes direct investments in technology-based companies. Based in central Manchester, we cater to funding, investment, and advisory needs, offering a unique model that supports companies from startup to exit. Our approach not only reassures our introduced investors but also provides ongoing mentoring and support during critical phases of an SME's lifecycle. We have successfully introduced over £150 million into UK SMEs, primarily through EIS (Enterprise Investment Scheme), and have executed successful exits for shareholders. At KPMG Acceleris, we continue to collaborate with some of the nation's most promising and disruptive companies.

BaseLaunch is the Basel-based incubator and accelerator that helps scientists and entrepreneurs launch exceptional biotech companies. It serves as a growth platform for early-stage ventures developing cutting-edge therapeutics. BaseLaunch helps build companies from inception through to Series A funding, providing financing and supporting all aspects of company creation and growth. It is operationally run and financed by Basel Area Business & Innovation, the investment and innovation promotion agency helping companies, institutions and startups find business success in the Basel area.